No connection

Search Results

KURA vs OMDA

KURA
Kura Oncology, Inc.
BEARISH
Price
$8.67
Market Cap
$765.8M
Sector
Healthcare
AI Confidence
85%
OMDA
Omada Health, Inc.
BEARISH
Price
$13.12
Market Cap
$773.1M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
KURA
--
OMDA
--
Forward P/E
KURA
-3.55
OMDA
36.59
P/B Ratio
KURA
4.37
OMDA
3.34
P/S Ratio
KURA
11.35
OMDA
2.97
EV/EBITDA
KURA
-0.39
OMDA
-84.98

Profitability

Gross Margin
KURA
-272.14%
OMDA
65.69%
Operating Margin
KURA
-497.62%
OMDA
4.33%
Profit Margin
KURA
0.0%
OMDA
-4.91%
ROE
KURA
-94.82%
OMDA
-8.68%
ROA
KURA
-25.33%
OMDA
-3.28%

Growth

Revenue Growth
KURA
-67.8%
OMDA
58.1%
Earnings Growth
KURA
--
OMDA
--

Financial Health

Debt/Equity
KURA
0.12
OMDA
--
Current Ratio
KURA
6.06
OMDA
3.6
Quick Ratio
KURA
5.81
OMDA
3.4

Dividends

Dividend Yield
KURA
--
OMDA
--
Payout Ratio
KURA
0.0%
OMDA
0.0%

AI Verdict

KURA BEARISH

KURA presents a contradictory profile with a stable Piotroski F-Score of 6/9 and exceptional liquidity (Current Ratio 6.06), yet suffers from severe fundamental decay. The company has experienced a catastrophic revenue decline of -67.80% YoY and has missed earnings estimates in four consecutive quarters with an average surprise of -50.91%. While the analyst target price of $31.82 suggests significant upside, this is decoupled from the current financial reality of negative gross margins (-272.14%) and bearish insider activity. The stock is currently a speculative play on pipeline success rather than a value or growth investment based on existing data.

Strengths
Strong liquidity position with a Current Ratio of 6.06
Very low leverage with a Debt/Equity ratio of 0.12
Stable Piotroski F-Score (6/9) indicating baseline operational stability
Risks
Severe revenue contraction (-67.80% YoY and Q/Q)
Consistent earnings misses (0/4 beats in the last year)
Deeply negative profitability (Operating Margin -497.62%)
OMDA BEARISH

OMDA exhibits a critical disconnect between high revenue growth and deteriorating financial health, evidenced by a weak Piotroski F-Score of 2/9. While the company shows strong top-line expansion (58.1% YoY) and positive earnings surprises, the technical trend is completely bearish and insider sentiment is heavily negative. The high current ratio provides a liquidity cushion, but the aggressive selling by the CEO and other executives suggests a lack of internal confidence in the current valuation. Despite analyst 'Buy' recommendations and a higher target price, the fundamental health and price action indicate significant risk.

Strengths
Strong revenue growth of 58.10% YoY
High gross margins at 65.69%
Strong short-term liquidity with a current ratio of 3.60
Risks
Very weak Piotroski F-Score (2/9) indicating poor fundamental health
Heavy insider selling, specifically by the CEO and CFO
Severe price depreciation (-48.4% over the last 6 months)

Compare Another Pair

KURA vs OMDA: Head-to-Head Comparison

This page compares Kura Oncology, Inc. (KURA) and Omada Health, Inc. (OMDA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile